Tamibaro
Tamibaro Uses, Dosage, Side Effects, Food Interaction and all others data.
Tamibaro is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibaro is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.
Tamibaro is a new synthetic retinoid drug recently approved for relapsed or refractory acute promyelocytic leukemia (APL) in Japan. It is a specific agonist for retinoic acid receptor alpha/beta. Compared to all-trans retinoic acid (ATRA), a natural retinoid indicated for a first-line treatment of APL, tamibarotene is chemically more stable and several times more potent as an inducer of differentiation in promyelocytic leukemia cells. In contrast to ATRA, whose plasma concentration declines considerably during daily administration, tamibarotene sustains plasma level probably due to a lower affinity for cellular retinoic acid binding protein. Furthermore, adverse side effects were milder than those of ATRA in clinical trials.
| Trade Name | Tamibaro |
| Generic | Tamibarotene |
| Tamibarotene Other Names | retinobenzoic acid, Tamibarotene |
| Type | |
| Formula | C22H25NO3 |
| Weight | Average: 351.4388 Monoisotopic: 351.183443671 |
| Protein binding | Over 99%, predominantly to serum albumin. |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in leukemia (unspecified).
How Tamibaro works
Tamibaro is a specific agonist for retinoic acid receptor alpha/beta with possible binding to retinoid X receptors (RXR).
Innovators Monograph
You find simplified version here Tamibaro
